Healthcare & Medical Devices Global On demand · 24-48h

Global Veterinary Rapid Test Market Strategic Research Report

Global Veterinary Rapid Test Market Strategic Research Repor…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Veterinary Rapid Test Market
$7722025
8.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Companion Test, Livestock Test

By Application: Veterinary Hospitals and Clinics, Laboratories

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: IDEXX Laboratories, Zoetis, Virbac, Thermo Fisher Scientific, SafePath Laboratories, BioNote, Heska, Fassisi, Chembio Diagnostic Systems, Bio-X Diagnostics, QUICKING BIOTECH, DRG International, Woodley Equipment Company, ScheBo Biotech, LifeAssays, Biopanda Reagents, SWISSAVANS, MEGACOR Diagnostik

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 139 pages
Market size 2025
$772
Million USD
Forecast CAGR
8.3%
2025-2032
Forecast 2032
$1349
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Veterinary Rapid Test market size is predicted to grow from US$ 772 million in 2025 to US$ 1,341 million in 2032; it is expected to grow at a CAGR of 8.3% from 2026 to 2032.

The test is based on a lateral flow immunochromatographic assay. The test device has a testing window. It has an invisible T(test) zone and C(control) zone. When a sample is applied into the specimen well on the device, the liquid will flow laterally along the surface of the test strip.

The main global Veterinary Rapid Test players include IDEXX Laboratories, Zoetis, Virbac, etc. The top three Veterinary Rapid Test players account for approximately 68% of the total market. North America is the largest consumer market for Veterinary Rapid Test, accounting for about 65%, followed by Europe and Asia-Pacific. In terms of type, Companion Test is the largest segment, with a share over 65%. And in terms of application, the largest application is Veterinary Hospitals and Clinics, followed by Laboratories.

This report presents a comprehensive overview of the global Veterinary Rapid Test market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Companion Test
  • Livestock Test

Segment by players, this report covers

  • IDEXX Laboratories
  • Zoetis
  • Virbac
  • Thermo Fisher Scientific
  • SafePath Laboratories
  • BioNote
  • Heska
  • Fassisi
  • Chembio Diagnostic Systems
  • Bio-X Diagnostics
  • QUICKING BIOTECH
  • DRG International
  • Woodley Equipment Company
  • ScheBo Biotech
  • LifeAssays
  • Biopanda Reagents
  • SWISSAVANS
  • MEGACOR Diagnostik

Segment by Application

  • Veterinary Hospitals and Clinics
  • Laboratories

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Veterinary Rapid Test market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Veterinary Hospitals and Clinics, Laboratories evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Veterinary Rapid Test Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$772
2025
Forecast
$1349
2032
CAGR
8.3%
2025–2032
Regiones
5
global
Key companies
IDEXX LaboratoriesZoetisVirbacThermo Fisher ScientificSafePath LaboratoriesBioNoteHeskaFassisi
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Companion TestLivestock Test
By Application
Veterinary Hospitals and ClinicsLaboratories

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Companion Test
  • 3.1.3 Livestock Test
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Veterinary Hospitals and Clinics
  • 4.1.3 Laboratories
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 IDEXX Laboratories
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Zoetis
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Virbac
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Thermo Fisher Scientific
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 SafePath Laboratories
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 BioNote
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Heska
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Fassisi
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Chembio Diagnostic Systems
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Bio-X Diagnostics
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 QUICKING BIOTECH
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 DRG International
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Woodley Equipment Company
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 ScheBo Biotech
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 LifeAssays
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Biopanda Reagents
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 SWISSAVANS
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 MEGACOR Diagnostik
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Veterinary Rapid Test market?
The global Veterinary Rapid Test market is estimated at US$ 772 million in 2025 (base year) and is projected to reach US$ 1.34 billion by 2032.
What is the forecast CAGR for the Veterinary Rapid Test market?
The market is expected to grow at a CAGR of 8.3% from 2026 to 2032, expanding from US$ 772 million in 2025 to US$ 1.34 billion in 2032, roughly 1.7 times its base-year value.
What is Veterinary Rapid Test?
The test is based on a lateral flow immunochromatographic assay. The test device has a testing window. It has an invisible T(test) zone and C(control) zone.
What are the main segments of the Veterinary Rapid Test market by type?
By type, the market is segmented into Companion Test and Livestock Test.
Which applications drive demand in the Veterinary Rapid Test market?
Key applications covered include Veterinary Hospitals and Clinics and Laboratories.
Who are the key players in the Veterinary Rapid Test market?
Key players profiled include IDEXX Laboratories, Zoetis, Virbac, Thermo Fisher Scientific, SafePath Laboratories, BioNote, Heska and Fassisi, among 18 companies covered in total.
Which regions and countries are covered for Veterinary Rapid Test?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Veterinary Rapid Test market report?
The report is intended for manufacturers and solution providers, distributors and end users in Veterinary Hospitals and Clinics and Laboratories, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Veterinary Rapid Test market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.